Article Versions Notes

Wang H-W, Lai H-C, Hu T-H, Su W-P, Lu S-N, Lin C-H, Hung C-H, Chuang P-H, Wang J-H, Lee M-H, et al. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. Cancers. 2020; 12(5):1177. https://doi.org/10.3390/cancers12051177

Wang, Hung-Wei, Hsueh-Chou Lai, Tsung-Hui Hu, Wen-Pang Su, Sheng-Nan Lu, Chia-Hsin Lin, Chao-Hung Hung, Po-Heng Chuang, Jing-Houng Wang, Mei-Hsuan Lee, and et al. 2020. "On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma" Cancers 12, no. 5: 1177. https://doi.org/10.3390/cancers12051177

Wang, H.-W., Lai, H.-C., Hu, T.-H., Su, W.-P., Lu, S.-N., Lin, C.-H., Hung, C.-H., Chuang, P.-H., Wang, J.-H., Lee, M.-H., Chen, C.-H., & Peng, C.-Y. (2020). On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. Cancers, 12(5), 1177. https://doi.org/10.3390/cancers12051177